COVID-19 Vaccines Show Small but Statistically Significant Association with Tinnitus
While COVID-19 vaccines demonstrate a small but statistically significant increase in new-onset tinnitus risk, the absolute risk remains very low (0.143% for mRNA vaccines), and this minimal risk must be weighed against the substantial mortality and morbidity benefits of vaccination, which remain strongly recommended for all persons aged ≥6 months 1.
Evidence Quality and Interpretation
The most recent and highest-quality evidence comes from a 2025 self-controlled case series study of 13,940 patients that found no increased tinnitus risk following COVID-19 XBB.1.5 vaccination, with relative incidences of 0.78 (95% CI: 0.67-0.90) for 14 days and 0.87 (95% CI: 0.78-0.96) for 28 days post-vaccination 2. This contradicts earlier findings but uses a more robust methodology that controls for individual-level confounding.
However, a 2026 large-scale TriNetX database study (180+ million records) found mRNA vaccination was associated with increased odds of tinnitus (OR 1.220; 95% CI: 1.189-1.252), though the absolute risk difference was only 0.143% 3. A 2024 Australian study using real-world general practice data similarly demonstrated increased tinnitus presentations following both mRNA vaccines (RI = 1.53, P <.001) and adenovirus vector vaccines (RI = 2.25, P <.001) 4.
Critical Context: COVID-19 Infection vs. Vaccination
Importantly, COVID-19 infection itself was NOT associated with increased tinnitus risk (OR 1.022; 95% CI: 0.997-1.048) 3. This is a crucial distinction—the disease poses no tinnitus risk while potentially causing severe illness and death, whereas vaccination shows minimal tinnitus risk while providing substantial protection against mortality and severe disease.
Clinical Implications
For Patient Counseling:
- Acknowledge the association: Small studies and case reports suggest a possible link between COVID-19 vaccination and new-onset or worsened tinnitus
- Quantify the absolute risk: Approximately 1-2 cases per 1,000 vaccinated individuals may develop tinnitus 3
- Emphasize reversibility: Most reported cases in clinical series showed variable outcomes, with many representing exacerbations of underlying conditions rather than permanent new pathology 5
- Compare to infection risk: COVID-19 infection itself does not increase tinnitus risk but carries substantial mortality risk, particularly in older adults 3
For Clinical Management:
- Any new-onset hearing loss with tinnitus post-vaccination should be evaluated promptly with audiometry and treated as sudden sensorineural hearing loss if confirmed (oral or intratympanic steroids) 6
- Isolated tinnitus without hearing loss often represents subjective tinnitus or temporomandibular joint syndrome rather than inner ear pathology 5
- The incidence of sudden sensorineural hearing loss in vaccinated patients (1.4%) is comparable to the general otology population, suggesting no causal relationship 5
Common Pitfalls to Avoid
Attribution bias: Many patients reporting tinnitus post-vaccination had underlying conditions (Meniere's disease, presbycusis) that were exacerbated rather than caused by vaccination 5
Concurrent COVID-19 infection: Studies could not fully account for concurrent or recent COVID-19 infections, which may confound the association 4
Surveillance bias: Increased awareness and reporting during the pandemic may inflate apparent associations 6
Bottom Line for Practice
The 2024 ACIP guidelines recommend COVID-19 vaccination for all persons aged ≥6 months, with demonstrated vaccine effectiveness of 49% against medically attended COVID-19 and 69% against critical illness 1. The potential for rare tinnitus cases does not alter this recommendation, as the mortality and morbidity benefits far outweigh this minimal risk. Any theoretical adverse events must be placed in context of preventing COVID-19 and its serious complications, including stroke and death 1.
For patients with pre-existing tinnitus or auditory concerns, vaccination should still proceed with appropriate counseling about the small absolute risk and plan for prompt audiological evaluation if symptoms develop.